Omeros | OMER - Selling And Administration Expenses


Omeros reported $11.32M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Adma Biologics USD 26.74M 6.55M Mar/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
BioMarin Pharmaceutical USD 395.55M 137.27M Jun/2026
Cytokinetics USD 104.4M 499K Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Immunic USD 3.45M 451K Dec/2025
Insmed USD 247.47M 208K Jun/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
MacroGenics USD 9.71M 1.77M Mar/2026
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 91.81M 7.93M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Rockwell Medical USD 4.04M 330K Jun/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 107.6M 53.57M Jun/2026
United Therapeutics USD 206.7M 50.1M Jun/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026